| Citation: |
CHEN Li-li, YU Yi-fei, ZENG Fang-fang, et al. Clinical value of 3rd generation assay of thyroid stimulating hormone receptor antibody (Elecsys) for differential diagnosis of thyrotoxicosis[J]. Chin J Clin Med, 2021, 28(1): 80-84. DOI: 10.12025/j.issn.1008-6358.2021.20201871
|
To explore the applicability of 3rd generation thyroid stimulating hormone receptor antibody (TRAb) assay (Elecsys) in clinical differentiation of thyrotoxicosis.
154 subjects with untreated thyrotoxicosis, who were admitted to Huashan Hospital between January 2016 and May 2018 were retrospectively selected. Thyroid function, TRAb, radioactive iodine uptake (RAIU), and mean peak systolic velocity of superior thyroid artery (STA-PSV) were detected. Receiver operating characteristic (ROC) curves were plotted to compare the value of the third generation TRAb and STA-PSV in the differential diagnosis of Graves'disease (GD) and destructive thyroiditis (DT).
Of the 154 subjects with untreated thyrotoxicosis enrolled, 111 (72.0%) were female, their mean age were 38.42 years. Totally, 117 (76.0%) were diagnosed as GD. The area under the ROC curve for TRAb in the differential diagnosis of thyrotoxicosis was 0.984 (95%CI 0.967-1.000), superior to that of STA-PSV (AUC 0.903, 95%CI 0.839-0.967). The best cutoff point of TRAb was 1.7 U/L, the sensitivity and specificity in distinguishing GD from DT were 94.8% and 94.3%, respectively. If TRAb cutoff point was set 3.6 U/L, its specificity and postive predictive value in GD differentiation reached 100%. There are 5 TRAb negative (< 1.7 U/L) GD cases, all of whom have significantly elevated STA-PSV.
The 3rd generation TRAb assay (Elecsys) is sensitive and specific in the differential diagnosis of thyrotoxicosis.
| [1] |
SMITH B R, HALL R. Thyroid-stimulating immunoglobulins in Graves' disease[J]. Lancet, 1974, 2(7878): 427-431. http://www.sciencedirect.com/science/article/pii/S0140673674918157
|
| [2] |
SOUTHGATE K, CREAGH F, TEECE M, et al. A receptor assay for the measurement of TSH receptor antibodies in unextracted serum[J]. Clin Endocrinol(Oxf), 1984, 20(5): 539-548. DOI: 10.1111/j.1365-2265.1984.tb00102.x
|
| [3] |
ZÖPHEL K, ROGGENBUCK D, SCHOTT M. Clinical review about TRAb assay's history[J]. Autoimmun Rev, 2010, 9(10): 695-700. DOI: 10.1016/j.autrev.2010.05.021
|
| [4] |
ZÖPHEL K, WUNDERLICH G, KOTZERKE J, et al. M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays[J]. Clin Chim Acta, 2009, 403(1-2): 266. DOI: 10.1016/j.cca.2009.01.022
|
| [5] |
KAMIJO K. Study on cutoff value setting for differential diagnosis between Graves' disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system[J]. Endocr J, 2010, 57(10): 895-902. DOI: 10.1507/endocrj.K10E-199
|
| [6] |
PEDERSEN I B, KNUDSEN N, PERRILD H, et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays[J]. Clin Endocrinol (Oxf), 2001, 55(3): 381-390. DOI: 10.1046/j.1365-2265.2001.01347.x
|
| [7] |
KAMIJO K. TSH-receptor antibody measurement in patients with various thyrotoxicosis and Hashimoto's thyroiditis: a comparison of two two-step assays, coated plate ELISA using porcine TSH-receptor and coated tube radioassay using human recombinant TSH-receptor[J]. Endocr J, 2003, 50(1): 113-116. DOI: 10.1507/endocrj.50.113
|
| [8] |
MORITA T, TAMAI H, OSHIMA A, et al. The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis[J]. J Clin Endocrinol Metab, 1990, 71(4): 1051-1055. DOI: 10.1210/jcem-71-4-1051
|
| [9] |
OTA H, AMINO N, MORITA S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease[J]. Clin Endocrinol (Oxf), 2007, 67(1): 41-45. DOI: 10.1111/j.1365-2265.2007.02832.x
|
| [10] |
ROSS D S, BURCH H B, COOPER D S, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421. DOI: 10.1089/thy.2016.0229
|
| [11] |
BOGAZZI F, VITTI P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease?[J]. Nat Clin Pract Endocrinol Metab, 2008, 4(2): 70-71. DOI: 10.1038/ncpendmet0692
|
| [12] |
MCKEE A, PEYERL F. TSI assay utilization: impact on costs of Graves' hyperthyroidism diagnosis[J]. Am J Manag Care, 2012, 18(1): e1-e14. http://europepmc.org/abstract/MED/22435785
|
| [13] |
KAHALY G J, BARTALENA L, HEGEDVS L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism[J]. Eur Thyroid J, 2018, 7(4): 167-186. DOI: 10.1159/000490384
|
| [14] |
SCHOTT M, HERMSEN D, BROECKER-PREUSS M, et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial[J]. Clin Endocrinol (Oxf), 2009, 71(4): 566-573. DOI: 10.1111/j.1365-2265.2008.03512.x
|
| [15] |
TOZZOLI R, KODERMAZ G, VILLALTA D, et al. Accuracy of receptor-based methods for detection of thyrotropin-receptor autoantibodies: a new automated third-generation immunoassay shows higher analytical and clinical sensitivity for the differential diagnosis of hyperthyroidism[J]. Auto Immun Highlights, 2010, 1(2): 95-100. DOI: 10.1007/s13317-010-0014-4
|
| [16] |
CARLÉ A, KNUDSEN N, PEDERSEN I B, et al. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study[J]. Eur J Endocrinol, 2013, 169(5): 537-545. DOI: 10.1530/EJE-13-0533
|
| [17] |
KAHALY G J. Bioassays for TSH receptor antibodies: quo vadis?[J]. Eur Thyroid J, 2015, 4(1): 3-5. DOI: 10.1159/000375445
|
| [18] |
KIM J J, JEONG S H, KIM B, et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay[J]. Scand J Clin Lab Invest, 2019, 79(6): 443-448. DOI: 10.1080/00365513.2019.1658216
|
| [19] |
HIRAIWA T, TSUJIMOTO N, TANIMOTO K, et al. Use of color Doppler ultrasonography to measure thyroid blood flow and differentiate Graves' disease from painless thyroiditis[J]. Eur Thyroid J, 2013, 2(2): 120-126. http://pubmedcentralcanada.ca/pmcc/articles/PMC3821509/
|
| [20] |
TOZZOLI R, D'AURIZIO F, VILLALTA D, et al. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease[J]. Clin Chem Lab Med, 2017, 55(1): 58-64. DOI: 10.1515/cclm-2016-0197
|
| [21] |
ROSARIO P W. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/L: a prospective study[J]. Clin Endocrinol (Oxf), 2010, 72(5): 685-688. DOI: 10.1111/j.1365-2265.2009.03696.x
|
DownLoad: